In addition to AML, SIRT5 overexpression has been reported in liver cancer, colorectal cancer, and other cancers and is often correlated with poor prognosis, suggesting that many tumors benefit from suppressing malonylation. Here, SIRT5 is linked to acute myeloid leukemia.